Revance Brings Mepivacaine-Based Fillers to US Market

Revance has announced the US launch of the Teoxane RHA^® Collection with Mepivacaine, marking a significant innovation in dermal filler formulations. The update reflects a shift in anesthetic agents used in hyaluronic acid fillers, with mepivacaine replacing lidocaine as the primary anesthetic agent, according to a company press release.

The updated collection received FDA approval in 2023 and is patented exclusively by Teoxane for use in dermal fillers. While mepivacaine is a new entrant to the aesthetics market, it has been used in therapeutic settings for more than six decades. Revance reports that mepivacaine functions via the same mechanism as lidocaine but causes less local vasodilation, potentially reducing injection site reactions such as bruising.

Preclinical and clinical trials comparing mepivacaine-containing products with those containing lidocaine demonstrated similar results in terms of pain control, safety, and aesthetic outcomes. The data suggest patients and providers may expect a similar level of efficacy with the added benefit of reduced side effects.

"The development of the Teoxane RHA® Collection with Mepivacaine exemplifies Teoxane's commitment to innovation," Teoxane founder and CEO Valerie Taupin said. "Mepivacaine represents the first major advancement in pain management for fillers in nearly two decades. It provides an anesthetic effect comparable to currently available products, but with reduced local vasodilation… which may result in less bruising. We are proud to bring this patented innovation to providers and offer great patient comfort. Teoxane is leading the way in a next-generation approach to optimal patient experience in aesthetics."

Revance CEO Jeff Bedard emphasized the company’s strategic objective of improving patient experiences without compromising aesthetic outcomes. The company positions the launch as a step toward next-generation aesthetic care in the competitive dermal filler market.